Breaking News, Collaborations & Alliances

Alteogen, Tesaro Agree to Develop Subcutaneous Form of Dostarlimab

Tesaro acquires worldwide rights to use a novel technology from Alteogen to develop and commercialize the formulation.

Author Image

By: Patrick Lavery

Content Marketing Editor

Alteogen and Tesaro, a subsidiary of GSK, reached an exclusive license agreement to develop a subcutaneous formulation of dostarlimab. Dostarlimab’s Indications Dostarlimab is a programmed death receptor-1 (PD-1) blocking antibody. In August 2024, GSK’s Jemperli (dostarlimab), combined with chemotherapy, was approved by the FDA. Its approved indication is for treatment of adult patients with advanced or recurrent endometrial cancer. In the agreement, Tesaro gains worldwide rights to use...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters